Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMNN-101 Phase 1/2 in Healthy Adults Previously Vaccinated Against SARS-CoV-2
NCT06283459Phase 2Completed
- Sponsor
- Imunon, Inc.
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of IMNN-101 in coronavirus disease 2019 (COVID-19), sponsored by Imunon, Inc.. Started Jun 2024; status: completed.
02
Drugs
IMNN-101
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06283459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06283459.